Citations

Institution: Mayo Clinic Clear

Showing 10 of 108083 citations.

Dose individualisation of antibiotics in critically ill patients with inflammation: A narrative review
Dräger, Sarah , Minichmayr, Iris K. , Alipanah, Narges , Frazee, Erin N. , Bos, Lieuwe D. J. , Fleuren, Lucas M. , Hunfeld, Nicole , Mathew, Sumith K. , Stocker, Sophie L. , Torres, Antoni , Alipanah-Lechner, Narges , Frazee, Erin N , Hunfeld, Nicole G M , Telles, João Paulo , Torres, Antoni , Koch, Birgit C P , Endeman, Henrik

British Journal of Clinical Pharmacology | August 15, 2025 | Volume: 91 | Issue: 11 | Pages: 3042-3053

10.1002/bcp.70185 | PMID 40813897 Get It

Due to extensive pathophysiological changes in critically ill patients, standard dosing of antibiotics may lead to inadequate drug exposure. This is concerning, as insufficient plasma drug concentrations may lead to treatment failure, whereas excessive drug exposure may increase the risk of toxic adverse events. The role of inflammation as a factor influencing the pharmacokinetics (PK) and pharmacodynamics (PD) of antibiotics remains largely unknown. PK/PD target attainment of antibiotics can be improved through therapeutic drug monitoring, i.e., measurement of drug concentrations in the blood with subsequent dosage adjustment to reach a certain target. Besides, population PK models may be used to predict drug exposure and tailor dosing in an individual patient (model‐informed precision dosing). Inflammatory biomarkers have been proposed to measure inflammation levels and guide antibiotic treatment. However, their potential to guide antibiotic dosing is unclear. This narrative review describes associations between inflammation and PK/PD of antibiotics in critically ill patients, and the role of biomarkers, therapeutic drug monitoring and model‐informed precision dosing in improving antibiotic dosing. A focus of future research should be on the interplay between inflammation and PK/PD of antibiotics by including inflammatory biomarkers in PK/PD models and using big data to predict antibiotic exposure in critically ill patients.
Patient-reported outcome measures used in clinical trials of an elbow orthosis: A scoping review
Ninow, Hadley T., Bhat, Sandesh G. , Wilson, Gwen , Barman, Apurba, Bhat, Sandesh G , Kaufman, Kenton R , Barman, Apurba , Kaufman, Kenton R.

Prosthetics & Orthotics International | August 15, 2025 | Volume: 50 | Issue: 3 | Pages: 330-340

10.1097/pxr.0000000000000482 | PMID 40814129 Get It

There is an increased clinical use of elbow orthoses. It is important to consider patient experiences in their use. Patient-reported outcome measures (PROMs) serve as essential tools for gathering patient perspectives. This review provides a comprehensive list of PROMs used in clinical trials of elbow orthoses, and documents their properties, uses, and quality. A systematic literature search across PubMed, Scopus, Embase, Cumulative Index to Nursing and Allied Health Literature, and Web of Science identified 31 clinical trials of elbow orthoses that used PROMs as outcome measures. Subsequently, manual searches were conducted to report on each PROM's characteristics. A total of 15 different PROMs were used as outcome measurements in clinical trials that used an elbow orthosis as an intervention for 11 different conditions. Researchers can use this review to aid in making informed decisions about which PROMs to use for future clinical trials.
Cardiovascular, kidney related, and weight loss effects of therapeutics for type 2 diabetes: a living clinical practice guideline
Agarwal, Arnav , Manja, Veena , Agoritsas, Thomas , MacDonald, Helen, Li, Sheyu , Rodríguez‐Gutiérrez, René , Heen, Anja Fog , Gabi, Jenan, Jeppesen, Britta Tendel, Jha, Vivekanand , Nagler, Evi, Odom, Adrienne, Rodondi, Nicolas, Wright, Robin, Vandvik, Per Olav , Agarwal, Arnav , Li, Sheyu , Mustafa, Reem A , Macdonald, Helen, Foroutan, Farid , Rayner, Daniel , Åsvold, Bjørn Olav , Guo, Lixin , Hao, Qiukui , Jeppesen, Britta Tendal, Rodondi, Nicolas , Shetty, Sahana , Vermandere, Mieke , Guyatt, Gordon

BMJ | August 15, 2025 | Volume: 390 | Issue: No issue available | Pages: e082071

10.1136/bmj-2024-082071 | PMID 40813129 Get It

Abstract Clinical question What are the benefits and harms of medications for adults with type 2 diabetes at varied risks of cardiovascular and kidney related complications? Context Emerging clinical trials of novel medications have demonstrated benefits on cardiovascular, kidney, and weight related outcomes in people with type 2 diabetes. Dynamically updated practice guidelines adhering to standards of trustworthiness are necessary in response to a rapidly evolving evidence base and the availability of multiple medication alternatives. This living practice guideline incorporates the latest available medications and evidence and provides recommendations stratified by risks of cardiovascular and kidney complications to inform diabetes management. Recommendations The panel issued risk-stratified recommendations regarding four prioritised medications for adults with type 2 diabetes (SGLT-2 inhibitors, GLP-1 receptor agonists, finerenone and tirzepatide): • Lower risk (three or fewer cardiovascular risk factors without established cardiovascular disease (CVD) or chronic kidney disease (CKD)): weak recommendation against SGLT-2 inhibitors or GLP-1 receptor agonists. • Moderate risk (more than three cardiovascular risk factors without established CVD or CKD; or established CVD and/or CKD at lower risk of complications): weak recommendation in favour of SGLT-2 inhibitors or GLP-1 receptor agonists; and a weak recommendation against finerenone in adults with CKD. • Higher risk (established CVD and/or CKD at higher risk of complications, or established heart failure): strong recommendation in favour of SGLT-2 inhibitors or GLP-1 receptor agonists; and a weak recommendation in favour of finerenone in adults with CKD. • Across risk strata: weak recommendation in favour of tirzepatide in adults with obesity. About this guideline and how it was created An international panel including two patient partners, clinicians, and methodologists produced these recommendations. The panel followed standards for trustworthy guidelines and used the GRADE approach, explicitly considering the balance of benefits, harms and burdens of treatment from an individual patient perspective. Recommendations were informed by a linked living systematic review and network meta-analysis evaluating relative benefits and harms updated to 31 July 2024; and by linked systematic reviews addressing risk prediction models and values and preferences of adults with type 2 diabetes. Candidate therapeutics are prioritised based on availability of sufficient randomised trial data, relevance to a global audience and likelihood of changing practice. This is the first version of the living guideline. The guideline is part of the BMJ Rapid Recommendations series. MAGICapp displays the most recent version of the guideline and full content including evidence summaries and decision aids; major updates will be published in The BMJ . We encourage re-use, adaptation and translation of these living guidelines, and recognise that the lack of availability or high costs of some medications may be prohibitive and will impact on how these recommendations are implemented across different health care systems.
Non-DLBCL monomorphic and Hodgkin lymphoma PTLD: clinical insights and treatment strategies
Atallah‐Yunes, Suheil Albert , Khurana, Arushi , Atallah-Yunes, Albert , Habermann, Thomas M.

Blood Advances | August 14, 2025 | Volume: 9 | Issue: 22 | Pages: 5792-5801

10.1182/bloodadvances.2025016930 | PMID 40811832 Get It

Abstract Monomorphic posttransplant lymphoproliferative disorders (PTLDs) beyond diffuse large B-cell lymphoma (DLBCL) are rare, biologically heterogeneous entities with limited prospective data to guide treatment. DLBCL-PTLD, which comprises most cases, is managed using approaches informed by prospective phase 2 studies, including reduction in immunosuppression and a risk-adapted sequential immunochemotherapy approach. In contrast, non-DLBCL subtypes such as Burkitt lymphoma, PTLDs of T/NK-cell origin, and plasmacytic variants are less common and are typically treated using strategies extrapolated from established treatment algorithms used in immunocompetent patients and sporadic case reports. Classic Hodgkin lymphoma PTLD, although not classified as monomorphic, represents another distinct and clinically relevant subtype. This review summarizes the epidemiology, clinical features, treatment strategies, and outcomes associated with these less common PTLDs, aiming to provide a practical framework for their management.
New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma
Greenbaum, Uri , Hashmi, Hamza , Elsawy, Mahmoud , Kim, Soyoung , Moskop, Amy , Oloyede, Temitope, Awan, Farrukh T. , Bachanová, Veronika , Badar, Talha , Bar, Merav , Barba, Pere , Cashen, Amanda F. , Ganguly, Siddhartha , Kittai, Adam S. , Lulla, Premal , Mead, Elena, Geethakumari, Praveen Ramakrishnan , Saber, Wael , Strouse, Christopher , Valluripalli, Anusha, Wudhikarn, Kitsada , Pasquini, Marcelo C. , Dholaria, Bhagirathbhai R , Farooq, Umar , Hematti, Peiman , Hill, LaQuisa C , Jain, Michael D , Jain, Tania , Lulla, Premal D , McGuirk, Joseph , Mussetti, Alberto , Nishihori, Taiga , Olson, Amanda L , Perales, Miguel-Angel , Riedell, Peter A , Shouval, Roni , Magalhaes-Silverman, Margarida , Pasquini, Marcelo , Ahmed, Sairah , Sorror, Mohamed , Bachanova, Veronika , Badar, Talha , Strouse, Christopher S , Awan, Farrukh T , Kim, Soyoung , Moskop, Amy , Beitinjaneh, Amer , Dholaria, Bhagirathbhai , Foglesong, Jessica , Hematti, Peiman , Hill, LaQuisa C. , Jain, Michael D. , Jain, Tania , Kebriaei, Partow , Locke, Frederick L. , McGuirk, Joseph P. , Mussetti, Alberto , Nishihori, Taiga , Pennisi, Martina , Perales, Miguel‐Angel , Riedell, Peter A. , Shpall, Elizabeth J. , Magalhaes‐Silverman, Margarida , Turtle, Cameron J. , Vallurupalli, Anusha , Ahmed, Sairah , Sorror, Mohamed L.

Blood Advances | August 14, 2025 | Volume: 10 | Issue: 1 | Pages: 217-227

10.1182/bloodadvances.2024015599 | PMID 40811818 Get It

Abstract The cumulative impact of baseline comorbidities on outcomes of chimeric antigen receptor T-cell (CAR-T) therapy is not well established. Therefore, we developed and validated a Cellular Therapy Comorbidity Index (CT-CI) to predict outcomes following CD19-directed CAR-T therapy for large B-cell lymphoma (LBCL). Patients aged 18 or older receiving commercial CAR-T therapy for LBCL during 2017 to 2020 were selected from the Center for International Blood and Marrow Transplant Research registry. Patients were randomly assigned to training or validation cohorts. Comorbidities given weighted scores comprised the CT-CI, which was then validated for overall survival (OS) prognostication. A total of 1916 patients from 97 medical centers were included, with a median age of 64 years (19-91 years). About 70% of patients had comorbidities, such as cardiac disease (12%); diabetes (14%); hepatic dysfunction (mild, 8%; moderate to severe, 2%); psychiatric disturbance (18%); and pulmonary dysfunction (moderate, 15%; severe, 12%). The CT-CI was calculated, stratified patients in 3 categories, and was associated with increased mortality. Patients with higher CT-CI scores had worse OS (CT-CI 1: hazard ratio [HR], 1.37 [95% confidence interval [CI], 1.16-1.62; P< .001]; CT-CI 2: HR, 1.49 [95% CI, 1.17-1.89; P = .001]; CT-CI ≥ 3: HR, 2.55 [95% CI, 1.90-3.42; P< .001]). Higher CT-CI scores predicted treatment-related mortality and relapse. There was no correlation between the CT-CI score and CAR-T–related toxicities. The novel CT-CI score stratifies the effect of patient comorbidities on survival after CAR-T therapy and can be used for clinical decision-making and treatment selection in high-risk populations. However, comorbidities and fear of increased toxicity should not preclude patients from this effective therapy.
Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study
Herrera, Alex F. , Ansell, Stephen M. , Zinzani, Pier Luigi , Maddocks, Kami J. , Pinto, Antonio , Collins, Graham P. , Bachanová, Veronika , Bartlett, Nancy L. , Bence‐Bruckler, Isabelle , Mayer, Jiří , Advani, Ranjana H. , Feldman, Tatyana , Hess, Brian , Szomor, Árpád, André, Marc, Dyczkowski, Jerzy, Havenith, Karin , Toukam, Marie , Pantano, Serafino, Cruz, Hans G. , Wang, Luqiang, Negievich, Yanina, Lucero, Melanie , Wuerthner, Jens, Carlo‐Stella, Carmelo , Radford, John , Pinto, Antonio , Bartlett, Nancy L , Hamadani, Mehdi , Savage, Kerry J , Casasnovas, René-Olivier , Iyengar, Sunil , Townsend, William , Cruz, Hans G , Carlo-Stella, Carmelo , Bachanova, Veronika , Zinzani, Pier Luigi , Advani, Ranjana H , Radford, John , Collins, Graham P., Hamadani, Mehdi , Kline, Justin Paul , Savage, Kerry J. , Caimi, Paolo F. , Casasnovas, Olivier , Bastos‐Oreiro, Mariana , Townsend, William

Blood Advances | August 14, 2025 | Volume: 9 | Issue: 23 | Pages: 6205-6217

10.1182/bloodadvances.2024015600 | PMID 40811783 Get It

Abstract Outcomes in classic Hodgkin lymphoma (cHL) have steadily improved; however, additional therapies are needed for patients who relapse or do not respond to novel agents. Here, we report the efficacy and safety of camidanlumab tesirine (Cami), an anti-CD25 antibody-drug conjugate, in patients with relapsed/refractory cHL after brentuximab vedotin/programmed cell death protein 1 inhibitor therapies from the phase 2 ADCT-301-201 study. Eligible patients were adults with cHL who had received ≥3 previous lines of systemic therapy (or ≥2 if ineligible for hematopoietic stem cell transplant). Patients received 45 μg/kg Cami (IV, once every 3 weeks) in cycles 1 to 2, followed by 30 μg/kg IV once every 3 weeks for ≤1 year. The primary end point was overall response rate (ORR) per 2014 Lugano classification. Secondary end points included complete response rate (CRR), progression-free survival (PFS), and overall survival (OS). In total, 117 patients were enrolled with a median age of 37.0 years (range, 19-87). The ORR was 70.1% (95% confidence interval [CI], 60.9-78.2), with a CRR of 33.3% (95% CI, 24.9-42.6). The median PFS was 9.13 months (95% CI, 5.3-15.0); median OS was not reached. Thirty-three (28.2%) patients discontinued treatment because of treatment-emergent adverse events; the most common reasons were skin and subcutaneous tissue disorders (n = 10 [8.5%] patients), infections and infestations (n = 5 [4.3%]), and nervous systems disorders (n = 5 [4.3%]). Guillain-Barré–type or polyradiculopathy-type events occurred in 8 (6.8%) patients. Cami was efficacious in this heavily pretreated population; however, the efficacy was overshadowed by substantial issues with the safety profile. This trial was registered at www.clinicaltrials.gov as #NCT04052997.
Teaching NeuroImage: Female Hormonal Therapy and Cerebral Cavernous Malformation Hemorrhage
Hooshmand, Sara , Flemming, Kelly D. , Hooshmand, Sara J , Flemming, Kelly D

Neurology | August 14, 2025 | Volume: 105 | Issue: 5 | Pages: No page available

10.1212/wnl.0000000000214081 | PMID 40811752 Get It

Low-Power Flexible Classifier Chip for Atrial Fibrillation Detection
Sanchez, Jose , Bhanushali, Sumukh Prashant , Sadasivuni, Sudarsan , Banerjee, Imon , Sanyal, Arindam , Banerjee, Imon

IEEE Transactions on Circuits and Systems for Artificial Intelligence | August 14, 2025 | Volume: 2 | Issue: 4 | Pages: 326-336

10.1109/tcasai.2025.3597591 | PMID 41550376 Get It

Setting the table for immune tolerance
Silverman, Michael A. , Knoop, Kathryn A. , Knoop, Kathryn, Knoop, Kathryn A

Science | August 14, 2025 | Volume: 389 | Issue: 6761 | Pages: 684-685

10.1126/science.adz8687 | PMID 40811563 Get It

Interaction between breast milk antibodies and gut microbes shape immune responses during weaning
Restless Legs Syndrome, Periodic Leg Movements, Hypertension and Cardiovascular Diseases
Dauvilliers, Yves , Chenini, Sofiène , Barateau, Lucie , Somers, Virend K. , Somers, Virend K. , Dauvilliers, Yves

Circulation Research | August 14, 2025 | Volume: 137 | Issue: 5 | Pages: 746-763

10.1161/circresaha.125.325677 | PMID 40811502 Get It

Restless legs syndrome (RLS) is a frequent sleep-related sensorimotor disorder defined by an urge to move the legs in the evening while resting. Severe RLS symptoms can negatively impact sleep, mood, and quality of life. Periodic leg movements during sleep and wakefulness are found in 60% to 80% of patients with RLS. The pathophysiology of RLS and periodic leg movement is still poorly understood and involves brain iron deficiency, dopamine dysregulation, and genetic predisposition. Over the past decades, several cross-sectional and longitudinal studies have reported an association between RLS, cardiovascular disease, and hypertension although the magnitude, direction, and underlying mechanisms of these associations remain inconclusive. Periodic leg movements during sleep are concomitant with an increase in blood pressure and heart rate, which may affect the physiological nocturnal blood pressure dip and, therefore, lead to an increased incidence of cardiovascular disease. Insomnia and sleep deprivation linked to sensory discomfort could also increase the sympathetic tone and contribute to an increase in cardiovascular risk. Comorbidities and associated sleep disorders may also synergically increase cardiovascular risk. This narrative review details the current knowledge of RLS, a still underdiagnosed and poorly recognized disorder, and examines the epidemiological relationship between RLS, cardiovascular disease and hypertension, potential mechanisms underlying this association, and strategies to reduce the risk of cardiovascular disease in patients with moderate-to-severe RLS. Greater multidisciplinary collaborations between cardiologists and sleep specialists are needed to better identify, understand, and manage patients with sleep disorders, including those with RLS.